ADCT · ADC Therapeutics SA

NYSEHealthcareBiotechnology

Adc Therapeutics Sa Is A Commercial-Stage Oncology-Focused Biotechnology Company. It Is Involved In The Development Of Antibody-Drug Conjugates For Patients Suffering From Hematological Malignancies And Solid Tumors. The Company'S Fda-Approved And Marketed Product, Zynlonta (Loncastuximab Tesirine), Is A Cd19-Directed Antibody And Alkylating Agent Conjugate Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory Large B-Cell Lymphoma After Two Or More Lines Of Systemic Therapy. Additionally, The Company'S Development Pipeline Comprises Lotis-2, Lotis-5, Lotis-7, And Adct-241, Being Developed As Potential Therapies For Different Cancer Diseases. Geographically, The Firm Generates Maximum Revenue From The United States, Followed By Europe, The Middle East And Africa (Emea).

HealthcareNYSECH

FLOAT

99.3M

FREE FLOAT %

78%

SHARES O/S

127.7M

MARKET CAP

$183.8M

EXCHANGE

NYSE

COUNTRY

ADCT Catalyst History

No catalysts recorded for ADCT yet

Day Trader Sniper hasn't classified a publishable catalyst for ADCT yet. New events appear here as they're scored.

Be early on the next ADCT spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

ADCT · ADC Therapeutics SA

ADCT Catalyst History

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.